ADTX · As filed with the SEC
Aditxt income statement, by quarter
The statement as Aditxt presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations (Unaudited) · USD, except per-share amounts
| USD, except per-share amounts | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025† 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 |
|---|---|---|---|---|
| REVENUE | ||||
| Sales | 12,159 | 425† | 748 | 1,004 |
| Cost of goods sold | 9,291 | 456† | 732 | 1,005 |
| Gross profit | 2,868 | (31)† | 16 | (1) |
| OPERATING EXPENSES | ||||
| General and administrative expenses $0 and $0 in stock-based compensation, respectively | 3,317,648 | 4,124,992† | 2,462,561 | 5,039,036 |
| Research and development $0 and $10,000 in stock-based compensation, respectively | 1,047,083 | 548,556† | 672,045 | 764,327 |
| Sales and marketing $0 and $0 in stock-based compensation, respectively | — | (3,995)† | 6,040 | 349,031 |
| Total operating expenses | 4,364,731 | 4,669,553† | 3,140,646 | 6,152,394 |
| NET LOSS FROM OPERATIONS | (4,361,863) | (4,669,584)† | (3,140,630) | (6,152,395) |
| OTHER INCOME (EXPENSE) | ||||
| Interest expense | (27,136) | (299,778)† | (176,527) | (47,352) |
| Interest income | 280 | (62,306)† | 183,631 | 78,566 |
| Amortization of debt discount | (24,687) | (60,000)† | (234,167) | (1,212,246) |
| Change in fair value of derivative liabilities | (11,800,798) | 228† | 162 | 980 |
| Change in fair value of Evofem warrants | 25,004 | 358,413† | 2,511,781 | (63,211) |
| Impairment of Evofem F-1 Preferred Stock | — | (764,290)† | (23,001,919) | — |
| Credit loss on Evofem notes | — | — | (350,000) | — |
| Total other expense | (11,827,337) | (561,667)† | (21,067,039) | (1,243,263) |
| Net loss before income taxes | (16,189,200) | (5,231,251)† | (24,207,669) | (7,395,658) |
| NET LOSS | (16,189,200) | (5,231,251)† | (24,207,669) | (7,395,658) |
| NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST | (241,475) | (529,572)† | (162,264) | (138,850) |
| NET LOSS ATTRIBUTABLE TO ADITXT, INC. & SUBSIDIARIES | (15,947,725) | (6,088,929)† | (24,045,405) | (7,256,808) |
| Net loss per share, basic (in Dollars per share) | (790.49) | — | (548.78) | (3.45) |
| Net loss per share, diluted (in Dollars per share) | (790.49) | — | (548.78) | (3.45) |
| Weighted average number of shares outstanding during the period, basic (in Shares) | 20,174 | — | 43,816 | 2,101,701 |
| Weighted average number of shares outstanding during the period, diluted (in Shares) | 20,174 | — | 43,816 | 2,101,701 |
| COMPREHENSIVE LOSS: | ||||
| Net Loss | (16,189,200) | — | — | — |
| Other Comprehensive Income: | ||||
| Change in fair value of Evofem note receivable | 107,805 | — | — | — |
| TOTAL COMPREHENSIVE LOSS | (16,081,395) | — | — | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.